News/ News/ R&D Amgen eyes swift move to ph3 for cardiovascular drug olpasiran Phil Taylor Amgen, atherosclerosis, gene silencing, lipoprotein(a), Novartis, olpasiran, pelacarsen, Silence Therapeutics, siRNA, SLN360 0 Comment Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible Share X Amgen eyes swift move to ph3 for cardiovascular drug olpasiran https://pharmaphorum.com/news/amgen-eyes-swift-move-to-ph3-for-cardiovascular-drug-olpasiran/